$TLSA Poised For An 85% Surge Amidst Alzheimer’s Drug Boom

Tiziana Life Sciences Ltd (NASDAQ: TLSA), a stock that has been under the radar, is now showing strong signals of a potential breakout. With a falling wedge pattern and a bullish RSI reading, coupled with the growing interest in Alzheimer’s drug development, TLSA is positioning itself as a stock to watch in 2025.

Technical Analysis
As of the time of writing, (NASDAQ: TLSA) shares are down 5.52%, but this dip is likely a temporary setback. The stock’s Relative Strength Index (RSI) stands at 52.77, which, despite the recent decline, suggests that bullish momentum is building. The RSI is neither overbought nor oversold, indicating a healthy consolidation phase before a potential upward move.

The most Intriguing technical indicator is the falling wedge pattern that has formed since January 23. This pattern is typically a bullish reversal signal, especially after a prolonged downtrend. The falling wedge is characterized by converging trendlines that slope downward, with the price making lower highs and lower lows. As the pattern nears its apex, the likelihood of a breakout increases.

For TLSA, the immediate support lies at the 78.6% Fibonacci retracement level. A pullback to this zone could serve as an excellent buying opportunity for traders, as it aligns with recent resistance-turned-support levels. On the upside, the 38.2% Fibonacci retracement level is acting as a pivot point. A breakout above this level could ignite a bullish rally, potentially propelling the stock toward an 85% surge.

Alzheimer’s Drugs – The Next Big Market Opportunity
While the technical setup is compelling, the story behind TLSA is equally intriguing. The Alzheimer’s drug market is emerging as the next big opportunity, drawing parallels to the obesity drug boom led by companies like Eli Lilly and Novo Nordisk. With an estimated market value of $13 billion by 2030, according to Bloomberg Intelligence, the race to develop effective Alzheimer’s treatments is heating up.

Companies like Biogen Inc., Eli Lilly & Co., Novo Nordisk, and Roche AG are investing billions into Alzheimer’s research. Recent developments have shown promise, with two new drugs—Leqembi (developed by Biogen and Eisai) and Kisunla (by Eli Lilly)—already approved in the U.S. These drugs target amyloid plaques in the brain, slowing the progression of the disease in its early stages. However, they are not without challenges, as side effects like brain bleeding and swelling have been reported.

For (NASDAQ: TLSA) stock, this presents a unique opportunity. If the company is involved in Alzheimer’s research or has partnerships with major pharmaceutical players, it could benefit significantly from the growing interest in this sector. Even if TLSA is not directly involved, the overall bullish sentiment in the healthcare and biotech sectors could provide a tailwind for the stock.

Additionally, any positive developments in Alzheimer’s drug trials or approvals could act as a catalyst for TLSA, driving the stock higher. As Gregoire Biollaz, senior investment manager at Pictet Asset Management, noted, “It could be a year where we also see a bit more clarity in terms of traction for the drugs that are approved so far.”


Conclusion
NASDAQ: TLSA is at a critical juncture, with both technical and fundamental indicators pointing to a potential surge. The falling wedge pattern suggest that the stock is building momentum, while the growing interest in Alzheimer’s drugs provides a strong fundamental catalyst. For investors seeking the next big opportunity, TLSA could be the stock to watch in 2025.

As always, investors should conduct their own due diligence and consider their risk tolerance before making any investment decisions. However, with an 85% surge on the horizon, TLSA is undoubtedly a stock worth keeping on your radar.